Neurogen cuts jobs

Neurogen said it laid off 70 workers and is taking a charge of about $1.5 million in the first quarter of 2008 to pay severence benefits and other charges.

The move is part of a restructuring to focus resources on advancing its pipeline of insomnia and other compounds including Phase II candidate aplindore for Parkinson's disease and restless legs syndrome.

Neurogen reported a net loss of $40 million for the nine months ended Sept. 30, 2007.
The job cut announcement came just days after Stephen Davis, a lawyer, became president and CEO. Davis succeeds William Koster, who has retired, but remains a director.
You must be a registered member of MMM to post a comment.

Next Article in Channel


Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.